Scientific Opinion on the modification of the authorisation of a health claim related to water‐soluble tomato concentrate and helps to maintain a healthy blood flow and benefits circulation pursuant to Article 13(5) of Regulation (EC) No 1924/2006 following a request in accordance with Article 19 of the Regulation (EC) No 1924/2006

Following an application from Provexis Natural Products Limited submitted pursuant to Article 19 of Regulation (EC) No 1924/2006 via the Competent Authority of United Kingdom, the Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on a request for modification of the authorisation of a health claim related to water‐soluble tomato concentrate and platelet aggregation. The modification concerns an extension of the authorised health claim to additional proposed conditions of use for powdered single‐serve sachets, tablets, and capsules. The scope of the application was proposed to fall under a health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data. The Panel considers that the food constituents, water‐soluble tomato concentrate I and II (i.e., in powder sachets, tablets and capsules), which are the subject of the claim are sufficiently characterised. The results of one unpublished study showed that the three water‐soluble tomato concentrate formulations reduced platelet aggregation as compared to the corresponding control and baseline values, with no significant differences between the three formulations. The Panel concludes that a cause and effect relationship has been established between the consumption of water‐soluble tomato concentrate I and II (corresponding to the specifications provided by the applicant) and a reduction in platelet aggregation under the new conditions of use proposed by the applicant (i.e., consumed as powder, tablets or capsules). © European Food Safety Authority, 2010